Indeed, only two drugs targeting chemokine receptors have been approved for clinical use so far, and they apply to very specific situations: HIV-1 infection in the case of the CCR5 antagonist maraviroc (13) and stem cell mobilization from the bone marrow (BM) in the case of the CXCR4 antagonist AMD3100 (plerixafor) (14). The gene discussed is CXCR4; the disease is HIV-1 infection.